Consequently, EGF treatment, and thus EGFR-signaling stimulation, might be protective in AD as it reduced skin inflammation of AD-like lesions in mice, enhanced skin barrier function, and improved Th1, Th2, and Th17 immune responses [98,99,100]. The gene discussed is EGF; the disease is dermatitis.